admin

When:Tuesday, July 30, 2019

Join Women In Bio-Capital Region to discuss one of the most important elements of entrepreneurship – how to determine whether to bring start-up team members in-house (and creatively convince them to work for your startup), or utilize vendors and contractors (and vet and manage them). We are excited to present an excellent panel of strong female professionals with diverse expertise in launching and facilitating successful businesses in the biotech space. Our panel will feature: Emily English, Ph.D. and CEO of Gemstone Biotherapeutics; Anne Balduzzi, Director of Advisory Services at TEDCO; and Maria Granovsky, Ph.D., J.D., and founder of Swimming Otter Communications. Dr. Ethel Rubin, Entrepreneur-in-Residence at BioHealth Innovation, Inc. will be our moderator for the evening, helping to highlight the panelists’ inspirational stories and cautionary tales of how to successfully start your own business (typically with little funding). Come prepared to listen, learn, ask questions, and have the opportunity to meet the leading ladies of our entrepreneurship-focused WIB evening. We can’t wait to see you there!

Venture funding raised by Maryland companies took a big jump in the second quarter of the year, as companies in the state raised a total of $226 million.

Chris Jeschke’s path into the startup world began with an unexpected outreach from an online advertising company. Following eight years at Advertising.com and four years at Booz Allen Hamilton, Jeschke is now CTO of Fells Point-based Protenus and building a team of next generation junior developers.

The Galien Foundation today announced the 2019 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry’s most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.

In a massive new analysis of findings from 277 clinical trials using 24 different interventions, Johns Hopkins Medicine researchers say they have found that almost all vitamin, mineral and other nutrient supplements or diets cannot be linked to longer life or protection from heart disease.

Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $1M from the Defense Threat Reduction Agency (DTRA, part of the US Department of Defense) to advance their work developing wearable sensors that measure biochemical information to diagnose disease. IBBR Fellow Dr. Gregory Payne (Research Professor, IBBR) is principal investigator on the award.

Health care and medical research may attract considerable philanthropic dollars from wealthy individuals, yet many givers question whether their dollars have an impact. 

Since the days of its founding, Johns Hopkins University has encouraged a spirit of innovation among its students and researchers. So it’s no surprise that many alumni go on to start their own companies.

Venture capital-backed companies based in the United States raised a record number of mega-rounds with 64 $100M+ deals this past quarter.

What is the NIH and how is NIH related to venture capital? Isn’t NIH a government research organization? NIH is widely recognized as the world’s premier biomedical research agency. Few realize that NIH, through its Small Business Innovation Research and Small Business Technology Transfer programs, is also the world’s largest early stage life sciences investor. We back over 1000 companies each year with over $1B! Companies that are awarded these much-coveted, non-dilutive awards for product development cannot do it alone. We need private, institutional and venture fund partners to help these companies bring products to market. That is where the investment world comes in.